To include your compound in the COVID-19 Resource Center, submit it here.

Catabasis' DMD candidate slows disease progression in Phase I/II

Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) reported data from the open-label extension of the Phase I/II MoveDMD trial showing that edasalonexent (CAT-1004) slowed disease progression in boys ages 4-7 with Duchenne muscular dystrophy (DMD). The company plans to start a registrational Phase III trial in 1H18 in

Read the full 451 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE